#Taiwan #Taipei #None #MolecuLight #Healtdeva

Major Breakthrough in Wound Care: MolecuLight's Impact

In a significant advancement for chronic wound management, MolecuLight Corp., a leader in point-of-care fluorescence imaging, has achieved remarkable results through a large independent randomized controlled trial (RCT). Conducted in collaboration with its Taiwanese distributor, Healtdeva Company Ltd., this pivotal study was carried out by clinicians at Shuang-Ho Hospital in Taipei.

The RCT, which enrolled 200 patients, titled Application of Perioperative Real-Time Fluorescence Imaging to Achieve High-Quality Debridement, is now published in the prestigious Advances in Wound Care Journal. The research rigorously analyzed the integration of MolecuLight's fluorescence imaging technology into standard surgical protocols for chronic wound debridement, revealing several crucial findings.

Enhanced Clinical Outcomes

This groundbreaking study highlights that utilizing MolecuLight devices not only improves the quality of surgical debridement but also significantly impacts clinical outcomes. The trial demonstrated a marked decrease in residual bacterial load when the imaging technology guided the surgical process, leading to:

• - Faster Healing Times: Patients undergoing the MolecuLight-guided debridement experienced wound healing in an average of 49 days, a stark contrast to 63 days observed in the standard care group.
• - Lower Infection Rates: The chance of post-surgical infections dramatically dropped, with infection rates at only 4% for the MolecuLight cohort compared to a troubling 22% for those receiving standard treatment.
• - Reduced Hospital Stays: On average, patients required only 18 days of hospitalization, compared to 22 days for their peers in the control group.
• - Economical Antibiotic Use: The trial reported a reduction in the duration of antibiotic treatment, leading to a 40% cost saving in antibiotic expenditures for the MolecuLight group.

Expert Insights

Dr. Shun-Cheng Chang, the senior author of the study and an Associate Professor at Shuang-Ho Hospital, remarked on the significance of the findings: "This randomized trial demonstrates that MolecuLight delivers measurable, clinically significant benefits in wound management. The ability to visualize bacterial burden in real-time allows surgeons to achieve higher-quality debridement and faster healing, while also serving as an invaluable teaching tool for training younger physicians in infection control and intraoperative wound assessment."

Wei-Pin Hsieh, CEO of Healtdeva, expressed pride in bringing this advanced technology to Taiwan's healthcare professionals, stating, "This RCT confirms what many clinicians are already seeing in practice—real-time fluorescence imaging empowers them to make more precise decisions, reduce complications, and improve patient outcomes."

A New Standard of Care

Anil Amlani, CEO of MolecuLight Corp., stated, “This landmark RCT provides the highest level of evidence validating our technology. These results not only showcase significant clinical benefits, such as faster healing and fewer reinfections but also demonstrate the economic value our system brings to chronic wound care.” He further commended the Shuang-Ho Hospital research team for their extraordinary work in advancing this field.

Overall, the study solidifies MolecuLight's crucial role in revolutionizing wound care and surgical treatment protocols globally. By providing real-time insights into bacterial presence, this innovative imaging platform equips clinicians with essential data, ultimately enhancing patient outcomes and transforming traditional wound management approaches.